Statistics suggests that specialists were less likely to explore new drugs. For 2013, the number of clinical trials has decreased by almost a quarter. Pharmaceutical services typically study generics (analogues of traditional means), instead of radically new products.
The output of any new drug is accompanied by appropriate tests. For 2013, the Ministry of health decided to implement 791 clinical trials. This figure is 25% less than in 2012.
Decreased and the number of international multicenter studies, including the Russian Federation. This indicator fell by 9.5%.
Representatives of the Ministry of health refer to the fact that a large number of companies are making serious mistakes when filling out applications for clinical trials. In addition, in 2012, came the law limiting the contact between pharmaceutical companies and physicians, which complicated the process of dissemination of information about new drugs.